Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: A systematic review

BACKGROUND: Treatment-resistant schizophrenia is prevalent and difficult to manage, as patients fail multiple antipsychotic trials before being considered as treatment-resistant. Currently clozapine is the only Food and Drug Administration-approved pharmacotherapy for treatment-resistant schizophren...

Descripción completa

Detalles Bibliográficos
Autores principales: Baig, Anum Iqbal, Bazargan-Hejazi, Shahrzad, Ebrahim, Gul, Rodriguez-Lara, Jaziel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5000
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545051/
https://www.ncbi.nlm.nih.gov/pubmed/34766570
http://dx.doi.org/10.1097/MD.0000000000027694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545051/
https://www.ncbi.nlm.nih.gov/pubmed/34766570
http://dx.doi.org/10.1097/MD.0000000000027694

Ejemplares similares